Moreover, previous studies by Dr. Saad Kenderian’s team and Dr. Julien Valton’s team demonstrated that GM-CSF inhibition reduced cytokine release syndrome in animal models4,5, supporting that GM-CSF KO will be a promising strategy in reducing CRS severity. The gene discussed is CSF2; the disease is congenital rubella syndrome.